IHCH-7086

In today's world, IHCH-7086 (person, topic, date, etc.) occupies a relevant place in society and in people's lives. Its influence extends to all areas, from culture to politics, through technology and economics. In this article, we will explore in depth the impact of IHCH-7086 and how it has shaped the world we live in. From its origins to its relevance today, we will analyze the different aspects that make IHCH-7086 a topic of interest to everyone. Through different points of view and studies, we will try to better understand the importance of IHCH-7086 in our society and in our lives.

IHCH-7086
Identifiers
  • (6bR,10aS)-2,3,6b,7,8,9,10,10a-octahydro-8--3-methyl-1H-Pyridopyrroloquinoxaline
CAS Number
PubChem CID
Chemical and physical data
FormulaC24H31N3O
Molar mass377.532 g·mol−1
3D model (JSmol)
  • CN(CCN12()3()CN(CCCC4=CC=CC=C4OC)CC2)C5=C1C3=CC=C5
  • InChI=InChI=1S/C24H31N3O/c1-25-15-16-27-21-12-14-26(13-6-8-18-7-3-4-11-23(18)28-2)17-20(21)19-9-5-10-22(25)24(19)27/h3-5,7,9-11,20-21H,6,8,12-17H2,1-2H3/t20-,21-/m0/s1
  • Key:WFYFRJAKNJVZMP-SFTDATJTSA-N

IHCH-7086 is a drug which acts as an agonist at the 5-HT2A serotonin receptor. It was derived by structural simplification of the 5-HT2A antagonist atypical antipsychotic drug lumateperone along with several related compounds such as IHCH-7079, which was found to be a non-hallucinogenic biased 5-HT2A agonist that was active in antidepressant assays but did not produce psychedelic-like responding in mice.[1][2][3] The related structure IHCH-7113 was found to produce a positive head-twitch response in mice, suggesting likely hallucinogenic activity in humans.

See also

References

  1. ^ US 6552017, Robichaud AJ, Lee T, Deng W, Mitchell IS, Yang MG, Haydar S, Chen W, Mc Clung CD, Calvello EJ, Zawrotny DM, "Substituted heterocycle fused gamma-carbolines.", issued 22 April 2003, assigned to Bristol Myers Squibb Pharma Co. 
  2. ^ US 9315504, Tomesch JC, Li P, Yao W, Zhang Q, Beard JD, Thompson AS, Cheng H, Wennogle LP, "Preparation of 4-((6BR,10AS)-3-methyl-2,3,6B,9,10, 10A-hexahydro-1H-pyridopyrrolo quinoxalin-8-(7H)-yl)-1-(4-fluorophenyl)-1-butanone or a pharmaceutically acceptable salt thereof", issued 19 April 2016, assigned to Intra Cellular Therapies Inc. 
  3. ^ Cao D, Yu J, Wang H, Luo Z, Liu X, He L, et al. (January 2022). "Structure-based discovery of nonhallucinogenic psychedelic analogs". Science. 375 (6579): 403–411. Bibcode:2022Sci...375..403C. doi:10.1126/science.abl8615. PMID 35084960. S2CID 246360313.


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.